• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves Bracco’s Lumason imaging agent

FDA approves Bracco’s Lumason imaging agent

October 16, 2014 By Alexander Soule

FDA approves Bracco's Lumason imaging agent

The FDA approved Bracco Diagnostics’ Lumason agent for patients whose ultrasound image of the heart are hard to see with ultrasound waves.

Marketed in other countries as SonoVue, Lumason is a contrast agent made up of gas-filled microbubbles, or microspheres, that reflect sound waves to enhance the image. Lumason helps a physician see a patient’s heart more clearly, allowing for clearer imaging of the left ventricle chamber and the smooth edge on the inside of chambers, known as the endocardium.

Of an estimated 28 million echocardiograms administered annually in the U.S., 10% or more of those exams are reported as suboptimal and possibly inconclusive, according to statistics cited by Bracco.

"Sometimes echocardiograms in certain patients are difficult for physicians to see and interpret," Dr. Libero Marzella of the FDA’s Center for Drug Evaluation & Research said in prepared remarks. "Today’s approval provides doctors with another option when performing contrast enhanced ultrasound."

Lumason’s safety and efficacy were established in 3 clinical trials involving nearly 200 patients with suspected cardiac disease whose echocardiograms were difficult to read and interpret. The most commonly reported side effects associated with Lumason were headache and nausea.

The FDA stated that all microbubble contrast agents, including Lumason’s sulfur hexafluoride lipid-type A microspheres, carry a boxed warning about the risk of serious cardiopulmonary reactions, including fatal cardiac or respiratory arrest. The risk of adverse reactions can increase for patients with certain heart conditions, with most serious reactions occurring within 30 minutes of administration.

Bracco Diagostics is located in Monroe Township, N.J., and is a subsidiary of Milan, Italy-based Bracco Imaging.

"We’re thrilled with the approval of Lumason as it represents a significant milestone in the company’s history," said Fulvio Renoldi Bracco, head of global business unit imaging at Bracco Imaging, in prepared remarks. "Today’s approval follows a long-term strategy of delivering the benefits of our contrast-enhanced ultrasound agent also in the U.S."

Filed Under: Cardiovascular, Food & Drug Administration (FDA), Imaging, News Well, Respiratory Tagged With: Bracco Diagnostics

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy